SCHEMBL1490705

SCHEMBL1490705

Cc1c(C)n2nnnc2c2nc(CON3C(=O)c4ccccc4C3=O)n(CCCCNC(=O)c3ccccc3)c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.38
HTR2A P28223 2/20 0.38
DRD3 P35462 2/20 0.38
BRD4 O60885 8/20 0.35
TNKS O95271 1/20 0.35
MAPT P10636 4/20 0.35
TP53 P04637 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HSP90AA1 P07900 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1490438 0.90 KMT2A (0.34) BRD4CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL1490895 0.87 TLR7 (0.42) KMT2ASMN1; SMN2
SCHEMBL1490250 0.86 EPHX1 (0.39) BRD4TP53MEN1NPC1ALDH1A1
SCHEMBL1490240 0.86 HTR1A (0.41) HTR1AHTR2ADRD3BRD4TNKS
SCHEMBL1490787 0.84 HTR1A (0.37) HTR1AHTR2ADRD3BRD4TNKS
SCHEMBL1490786 0.84 HTR1A (0.37) HTR1AHTR2ADRD3BRD4TNKS
SCHEMBL1490694 0.84 HTR1A (0.37) HTR1AHTR2ADRD3BRD4TNKS
SCHEMBL5635471 0.80 TDP1 (0.36) MAPTMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL1490755 0.80 ALDH1A1 (0.35) MEN1ALDH1A1KMT2A
SCHEMBL4792410 0.78 TDP1 (0.40) MAPTMEN1ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598192-B2 Hydroxylamine substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-12-03 US disclosed
US-7897767-B2 Oxime substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-03-01 US disclosed
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-04-23 US disclosed
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES COLEY PHARMACEUTICAL GROUP, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105295-A1 HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES IL2, IL4, IFNG HTR1A 729/4885HTR2A 311/4885DRD3 2609/4885
US-20090042925-A1 OXIME SUBSTITUTED IMIDAZOQUINOLINES IFNG, IL2, IRF3 HTR1A 4171/4885HTR2A 3237/4885DRD3 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.